Companies to apply technology originally developed to address drug safety, to pricing accuracy, chargeback automation, and other supply chain solutions
SAN FRANCISCO, Jan. 21, 2022 /PRNewswire/ -- Chronicled, the technology company behind MediLedger Network, has entered into a partnership with Parity Technologies, the developer behind Polkadot and Substrate; together the two will leverage modern peer-to-peer communication and blockchain technologies to improve the integrity and efficiency of the Life Sciences supply chain.
The MediLedger Network is the leading blockchain-powered network for automatically settling trading partner transactions in the Life Sciences industry. Over 77 pharmaceutical firms are participating in the MediLedger Network, including 9 of the top 10 pharmaceutical manufacturers, as well as leading healthcare distributors and Group Purchasing Organizations (GPOs).
MediLedger was developed using Parity's blockchain framework, Substrate, which also powers Polkadot, the 8th largest cryptocurrency by market cap.
MediLedger was initially created to tackle drug supply chain safety, and under this new partnership that framework will be applied across a diverse range of areas, including: product data verification on drugs returned to distributors, and settling drug discount reimbursements between manufacturers and distributors (chargebacks).
Substrate provides unparalleled flexibility for MediLedger, enabling the development of blockchain solutions to meet the demands of any use case. At present, MediLedger solutions utilize a permissioned network configuration, and their new capacity to interoperate with other blockchains such as Polkadot, creates an exciting wealth of opportunities for innovation with permissioned and/or public hybrid use cases, or tokenization within Life Sciences.
"We discover exciting new use cases every day for the application of blockchain and Web 3.0 technologies," says Susanne Somerville, CEO of Chronicled. "Substrate has been designed to adapt to the future, and will enable us to innovate and fulfil whatever needs the industry requires of us"
Pricing discounts offered to pharmaceutical dispensers across the U.S. are governed by the contracting and chargeback processes, which have historically been supported by dated technology such as EDI, and in some cases, emails and spreadsheets. Through MediLedger, partners can align on customer eligibility and pricing in real-time, all the while maintaining chargeback accuracy prior to claims being shared with suppliers.
It's a breakthrough for the industry, and will reduce the industry error rates from approximately 4% to around 0.1% across multiple pain points such as: chargeback disputes, pricing errors, and inefficiencies impacting cash flow.
1 References https://www.mckesson.com/Pharmacy-Management/Health-Systems/Prescribed-Perspectives/Contract-Alignment-and-Chargebacks/
About Parity
Parity Technologies is a core blockchain infrastructure company. It is creating an open-source creative commons that will enable people to create better institutions through technology. This started with work building Ethereum. Today, Parity is focused on Substrate, an industry-standard blockchain framework. It has used it to build Polkadot, a decentralized web blockchain meta-protocol, securing and connecting crypto-economies to the world.
About Chronicled
Chronicled, a San Francisco-based technology company, enables automation, trust, and automatic settlement for inter-company transactions in the Life Sciences and Healthcare industry. Through the industry leading blockchain-powered MediLedger Network, Chronicled offers trading partners a new way to manage revenue, automate manual processes, and eliminate revenue leakage, while ensuring pricing accuracy and efficiency for health care providers and dispensers. To learn more, visit www.chronicled.com.
Logo: https://mma.prnewswire.com/media/1712696/Polkadot_Logo.jpg
Logo: https://mma.prnewswire.com/media/1731380/Chronicled_Logo.jpg
Media contact
Úrsula O'Kuinghttons
Director of Public Relations
ursula@parity.io
+34 619 636 958
Share this article